Sarepta Therapeutics Inc [SRPT] stock is trading at $122.41, up 3.75%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SRPT shares have gain 3.07% over the last week, with a monthly amount drifted -4.66%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, RBC Capital Mkts upgraded its rating to Outperform on July 29, 2024, and kept the price target unchanged to $182. On June 26, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $176 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $157 on May 31, 2024. RBC Capital Mkts downgraded its rating to a Sector Perform and reduced its price target to $142 on May 28, 2024. Oppenheimer upgraded its rating to Outperform for this stock on May 14, 2024, but kept the price target unchanged to $180. In a note dated January 31, 2024, BMO Capital Markets initiated an Outperform rating and provided a target price of $170 on this stock.
Sarepta Therapeutics Inc [SRPT] stock has fluctuated between $55.25 and $173.25 over the past year. Currently, Wall Street analysts expect the stock to reach $169.93 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $122.41 at the most recent close of the market. An investor can expect a potential return of 38.82% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
Sarepta Therapeutics Inc [NASDAQ:SRPT] reported sales of 1.50B for the trailing twelve months, which represents a growth of 38.93%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at 0.04%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.05 and Total Capital is 0.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 119.01 points at the first support level, and at 115.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 125.24, and for the 2nd resistance point, it is at 128.06.
Ratios To Look Out For
For context, Sarepta Therapeutics Inc’s Current Ratio is 3.90. As well, the Quick Ratio is 3.19, while the Cash Ratio is 0.56. Considering the valuation of this stock, the price to sales ratio is 7.76, the price to book ratio is 10.83 and price to earnings (TTM) ratio is 302.62.
Transactions by insiders
Recent insider trading involved Estepan Ian Michael, Chief Financial Officer, that happened on Aug 30 ’24 when 5985.0 shares were sold. Officer, Estepan Ian Michael completed a deal on Aug 30 ’24 to buy 5985.0 shares. Meanwhile, Director Chambers Michael Andrew bought 37038.0 shares on Aug 16 ’24.
